News stories about Nymox Pharmaceutical (NASDAQ:NYMX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.5106821759104 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Nymox Pharmaceutical (NASDAQ NYMX) traded down $0.07 on Friday, hitting $3.31. The stock had a trading volume of 87,799 shares, compared to its average volume of 85,452. Nymox Pharmaceutical has a 12-month low of $2.67 and a 12-month high of $5.10. The company has a debt-to-equity ratio of 61.64, a quick ratio of 1.42 and a current ratio of 1.44. The stock has a market cap of $185.33, a price-to-earnings ratio of 10.68 and a beta of 0.82.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at

About Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with's FREE daily email newsletter.